- Home
- CAN vs STOK Comparison
CAN vs STOK Comparison
Compare CAN & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAN
- STOK
- Stock Information
- Founded
- CAN 2013
- STOK 2014
- Country
- CAN Singapore
- STOK United States
- Employees
- CAN N/A
- STOK N/A
- Industry
- CAN Semiconductors
- STOK Biotechnology: Pharmaceutical Preparations
- Sector
- CAN Technology
- STOK Health Care
- Exchange
- CAN Nasdaq
- STOK Nasdaq
- Market Cap
- CAN 384.3M
- STOK 379.6M
- IPO Year
- CAN 2019
- STOK 2019
- Fundamental
- Price
- CAN $0.70
- STOK $7.69
- Analyst Decision
- CAN Strong Buy
- STOK Strong Buy
- Analyst Count
- CAN 4
- STOK 6
- Target Price
- CAN $3.88
- STOK $26.00
- AVG Volume (30 Days)
- CAN 16.3M
- STOK 987.9K
- Earning Date
- CAN 05-16-2025
- STOK 05-05-2025
- Dividend Yield
- CAN N/A
- STOK N/A
- EPS Growth
- CAN N/A
- STOK N/A
- EPS
- CAN N/A
- STOK N/A
- Revenue
- CAN $269,324,000.00
- STOK $36,555,000.00
- Revenue This Year
- CAN $161.88
- STOK $27.80
- Revenue Next Year
- CAN $35.55
- STOK $9.53
- P/E Ratio
- CAN N/A
- STOK N/A
- Revenue Growth
- CAN 27.35
- STOK 316.34
- 52 Week Low
- CAN $0.65
- STOK $5.35
- 52 Week High
- CAN $3.27
- STOK $17.58
- Technical
- Relative Strength Index (RSI)
- CAN 32.99
- STOK 53.59
- Support Level
- CAN $0.65
- STOK $7.31
- Resistance Level
- CAN $0.77
- STOK $7.99
- Average True Range (ATR)
- CAN 0.07
- STOK 0.61
- MACD
- CAN 0.01
- STOK 0.23
- Stochastic Oscillator
- CAN 19.48
- STOK 88.64
About CAN Canaan Inc.
Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment as well as the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.